Fluoroquinolone antibiotics can increase the occurrence of rare but serious events of ruptures or tears in the aorta, FDA said in a new warning.
Fluoroquinolone antibiotics can increase the occurrence of rare but serious events of ruptures or tears in the aorta, FDA said in a new warning.
“These tears…or ruptures of an aortic aneurysm can lead to dangerous bleeding or even death. They can occur with fluoroquinolones for systemic use given by mouth or through an injection,” FDA said in a MedWatch Safety Alert.
Fluoroquinolones include ciprofloxacin (Cipro), levofloxacin (Levaquin), and Ofloxacin generic brands.
Related: New antibiotic treats hospital-acquired infections
While this class of antibiotics has been used for more than 30 years, FDA is now saying that healthcare professionals should avoid prescribing fluoroquinolone antibiotics to patients who have an aortic aneurysm or are at risk for an aortic aneurysm.
Patients at risk for an aortic aneurysm include those with peripheral atherosclerotic vascular diseases, hypertension, certain genetic conditions such as Marfan syndrome and Ehlers-Danlos syndrome, and elderly patients.
Related: Pharma exec defends 400% price hike
"Prescribe fluoroquinolones to these patients only when no other treatment options are available,” FDA said.
While FDA originally investigated the association between fluoroquinolone antibacterial use and the risk of aortic aneurysm and dissection in 2015, 3 newer studies found an increased risk of aortic aneurysm or dissection associated with fluoroquinolone use, according to the agency.
FDA also found 56 cases of aortic aneurysm or dissection reported during or after treatment with a fluoroquinolone in its FDA Adverse Event Reporting database from December 15, 2015, through April 30, 2018.
Read more: FDA warns maker of ingredient In huge heart drug recall
Get the latest industry news, event updates, and more from Managed healthcare Executive.
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
August 1st 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
FDA Extends Review of Blenrep Combinations in Multiple Myeloma
August 1st 2025Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing and tolerability. The new action date is Oct. 23, 2025.
Read More
Sarepta to Pause Shipments of the Gene Therapy Elevidys
August 1st 2025Sarepta officials said the temporary halt in shipments was done to maintain a productive working relationship with regulators while they address a safety labeling update about the risk of acute liver disease related to Elevidys.
Read More